- Conditions
- Diabetes, Coronary Artery Disease
- Interventions
- ALT-2074
- Drug
- Lead sponsor
- Synvista Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 18,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uncontrolled Hypertension, Resistant Hypertension
- Interventions
- Baxdrostat, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
- Conditions
- Obesity, Dyslipidemia
- Interventions
- Rimonabant (SR141716)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,033 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 28
- States / cities
- Mesa, Arizona • Tucson, Arizona • Irvine, California + 25 more
- Conditions
- Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- INOpulse®, Placebo, Open Label Extension
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more
- Conditions
- Fibromyalgia
- Interventions
- Xyrem (sodium oxybate) oral solution, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 17 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Amniotic Fluid, Saline Placebo
- Other
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Des Plaines, Illinois + 1 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 29
- States / cities
- Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
- Conditions
- Major Depressive Disorder
- Interventions
- Cariprazine, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Patritumab, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Glendale, Arizona • Duarte, California • La Verne, California + 23 more
- Conditions
- Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
- Interventions
- Apraglutide, Placebo
- Drug
- Lead sponsor
- VectivBio AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis
- Interventions
- Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Reno, Nevada
- Conditions
- COVID-19
- Interventions
- Placebo for SLV213, SLV213
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
- Conditions
- Neuromuscular Blockade
- Interventions
- Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline, Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Beta-Thalassemia
- Interventions
- VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID, Placebo
- Drug
- Lead sponsor
- Vifor (International) Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Whittier, California
- Conditions
- Healthy Volunteers
- Interventions
- Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose)
- Biological · Other
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Betaseron (Interferon beta-1b, BAY86-5046)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
- Conditions
- Major Depressive Disorder
- Interventions
- Agomelatine (AGO178C), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- Alpelisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Days to 100 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more
- Conditions
- Pain, Osteoarthritis, Knee
- Interventions
- Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch
- Drug
- Lead sponsor
- ZARS Pharma Inc.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 5
- States / cities
- Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Tadalafil, Placebo, ERA as specific PAH treatment
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 13 more